-- Target diseases for this collaboration are Diffuse Large Cell Lymphoma,
Transformed Follicular Lymphoma, and Chronic Lymphocytic Leukemia
-- Collaboration to develop microRNA-based diagnostics test, early
detection and prognosis. -- 43,000 people will be diagnosed with these types of cancers in 2007 in
the US alone(1) -- MicroRNAs hold significant potential as highly sensitive and specific
biomarkers for hematological cancers -- Collaboration also will seek to identify microRNA (miRNA) targets for
REHOVOT, Israel and NEW YORK, Dec. 13 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (Nasdaq: ROSG) and Columbia University Medical Center announced today they will collaborate to develop microRNA-based diagnostic tests, early detection as well as prognosis, for Diffuse Large Cell Lymphoma, Transformed Follicular Lymphoma, and for Chronic Lymphocytic Leukemia. Three types of Non- Hodgkin Lymphoma (NHL).
"We are constantly expanding our pipeline with new diagnostic and therapeutic programs, both cancer and non-cancer related, in order to maximize our leading position in microRNA intellectual property and proprietary technologies", noted Amir Avniel, President and CEO of Rosetta Genomics. "We are very excited to be collaborating with a leading research institution such as Columbia University Medical Center, and hope more collaboration will follow."
Combining Rosetta Genomics know-how and proprietary technologies with Columbia University Medical Center's expertise in cancer, researchers will screen for microRNAs that may be used as potential biomarkers and drug targets for these NHL indications.
Diffuse Large Cell Lymphoma (DLCL) and Transformed Follicular Lymphoma are the two most common types of NHL, accounting for approximately 45 percent of all new non NHL cases. Chronic Lymphocytic Leukemia (CLL) is a type of cancer that starts in blood-forming cells of the bone marrow. It then invades the blood and can spread to other parts of the body, including the spleen. According to the American Cancer Society, in the US alone approximately 43,000 people will be diagnosed with these types of cancers in 2007.
"40 percent of DLCL patients respond well to current therapies and have prolonged survival, whereas the remainder succumb to the disease, and we do not know why," said Dalia Cohen, Global Head of R&D at Rosetta Genomics. "We believe our technology will help answer this question, as well as speed up and simplify the diagnostic process."
"MicroRNAs perform their regulatory function on key cellular processes further up-stream than other currently used biomarkers," explained Dr. Riccardo Dalla-Favera, professor of Pathology, director of the Institute for Cancer Genetics and the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center. "This is most likely the reason why they are proving to be such good biomarkers. The technologies developed through our collaboration with Rosetta Genomics are very sensitive. Our hope is that by working together, we can continue to take important steps toward better diagnostic tests for cancer patients."
MicroRNAs (miRNAs) are recently discovered, naturally occurring small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression levels in certain diseased versus normal tissues. As a result, these differences potentially provide for a novel diagnostic strategy for many diseases. MicroRNAs are thought to play a key role in the differentiation of cells into specific cell types performing various functions in the body.
About Columbia University
Columbia University Medical Center provides international leadership in basic, pre-clinical and clinical research, in medical and health sciences education, and in patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians & Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. http://www.cumc.columbia.edu
About Rosetta Genomics
Rosetta Genomics (Nasdaq: ROSG) is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostic and therapeutic products based on microRNAs. The company's primary focus is in the development of microRNA- based products to diagnose and treat different forms of cancer and infectious diseases.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future
expectations, plans and prospects, including without limitation, statements
relating to the role of microRNAs in human physiology and disease,
including heart disease, and the potential of microRNAs in the diagnosis
and treatment of disease constitute forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by these forward- looking statements as a result of various
important factors, including risks related to: Rosetta's approach to
discover and develop novel diagnostics and therapeutic products, which is
unproven and may never lead to marketable products; Rosetta's ability to
fund and the results of further pre-clinical and clinical trials; Rosetta's
ability to obtain, maintain and protect the intellectual property utilized
by Rosetta's products; Rosetta's ability to enforce its patents against
infringers and to defend its patent portfolio against challenges from third
parties; Rosetta's ability to obtain additional funding to support its
business activities; Rosetta's dependence on third parties for development,
manufacture, marketing, sales, and distribution of products; Rosetta's
ability to successfully develop its product candidates, all of which are in
early stages of development; Rosetta's ability to obtain regulatory
approval for products; competition from others using technology similar to
Rosetta's and others developing products for similar uses; Rosetta's
dependence on collaborators; and Rosetta's short operating history; as well
as those risks more fully discussed in the "Risk Factors" section of
Rosetta's Annual Report on Form 20-F for the year ended December 31, 2006
as filed with the Securities and Exchange Commission. In addition, any
forward- looking statements represent Rosetta's views only as of the date
of this release and should not be relied upon as representing its views as
of any subsequent date. Rosetta does not assume any obligation to update
any forward- looking statements unless required by law.
(1) Source : American Cancer Society, http://www.cancer.org
University Medical Center. "This is most likely the reason why they
are proving to be such good biomarkers. The technologies developed
through our collaboration with Rosetta Genomics are very sensitive.
Our hope is that by working together, we can continue to take
important steps toward better diagnostic tests for cancer patients."
|SOURCE Rosetta Genomics|
Copyright©2007 PR Newswire.
All rights reserved